## Thomas J Hannan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7419512/publications.pdf

Version: 2024-02-01

25 papers 2,088 citations

304743

22

h-index

610901 24 g-index

28 all docs 28 docs citations

28 times ranked

2313 citing authors

#	Article	IF	CITATIONS
1	Host–pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic <i>Escherichia coli</i> bladder infection. FEMS Microbiology Reviews, 2012, 36, 616-648.	8.6	296
2	Early Severe Inflammatory Responses to Uropathogenic E. coli Predispose to Chronic and Recurrent Urinary Tract Infection. PLoS Pathogens, 2010, 6, e1001042.	4.7	223
3	Donor-Strand Exchange in Chaperone-Assisted Pilus Assembly Proceeds through a Concerted $\hat{l}^2$ Strand Displacement Mechanism. Molecular Cell, 2006, 22, 831-842.	9.7	159
4	Bacterial virulence phenotypes of <i>Escherichia coli</i> and host susceptibility determine risk for urinary tract infections. Science Translational Medicine, 2017, 9, .	12.4	139
5	Dysregulation of <i>Escherichia coli</i> $\hat{l}$ ±-hemolysin expression alters the course of acute and persistent urinary tract infection. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E871-80.	7.1	132
6	A FimH Inhibitor Prevents Acute Bladder Infection and Treats Chronic Cystitis Caused by Multidrug-Resistant Uropathogenic Escherichia coli ST131. Journal of Infectious Diseases, 2013, 208, 921-928.	4.0	116
7	Inhibition of Cyclooxygenase-2 Prevents Chronic and Recurrent Cystitis. EBioMedicine, 2014, 1, 46-57.	6.1	92
8	Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections. Microbiology Spectrum, 2016, 4, .	3.0	87
9	Enterococcus faecalis Overcomes Foreign Body-Mediated Inflammation To Establish Urinary Tract Infections. Infection and Immunity, 2013, 81, 329-339.	2.2	84
10	Antivirulence <i>C</i> -Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract Infections. Journal of Medicinal Chemistry, 2016, 59, 9390-9408.	6.4	84
11	Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease. Expert Opinion on Drug Discovery, 2017, 12, 711-731.	5.0	71
12	<i>LeuX</i> tRNAâ€dependent and â€independent mechanisms of <i>Escherichia coli</i> pathogenesis in acute cystitis. Molecular Microbiology, 2008, 67, 116-128.	2.5	67
13	A mucosal imprint left by prior Escherichia coli bladder infection sensitizes to recurrent disease. Nature Microbiology, 2017, 2, 16196.	13.3	67
14	Role of Hypoxia Inducible Factor- $1\hat{l}\pm$ (HIF- $1\hat{l}\pm$ ) in Innate Defense against Uropathogenic Escherichia coli Infection. PLoS Pathogens, 2015, 11, e1004818.	4.7	62
15	Longitudinal multi-omics analyses link gut microbiome dysbiosis with recurrent urinary tract infections in women. Nature Microbiology, 2022, 7, 630-639.	13.3	54
16	Subinhibitory Antibiotic Therapy Alters Recurrent Urinary Tract Infection Pathogenesis through Modulation of Bacterial Virulence and Host Immunity. MBio, 2015, 6, .	4.1	52
17	A Murine Model for Escherichia coli Urinary Tract Infection. Methods in Molecular Biology, 2016, 1333, 159-175.	0.9	50
18	Evolutionary fine-tuning of conformational ensembles in FimH during host-pathogen interactions. Science Advances, 2017, 3, e1601944.	10.3	50

#	Article	IF	CITATION
19	Uropathogenic Escherichia coli Superinfection Enhances the Severity of Mouse Bladder Infection. PLoS Pathogens, 2015, 11, e1004599.	4.7	46
20	Are you experienced? Understanding bladder innate immunity in the context of recurrent urinary tract infection. Current Opinion in Infectious Diseases, 2015, 28, 97-105.	3.1	42
21	Distinguishing the Contribution of Type 1 Pili from That of Other QseB-Misregulated Factors when QseC Is Absent during Urinary Tract Infection. Infection and Immunity, 2012, 80, 2826-2834.	2.2	35
22	Host restriction of Escherichia coli recurrent urinary tract infection occurs in a bacterial strain-specific manner. PLoS Pathogens, 2018, 14, e1007457.	4.7	32
23	Mucosal infection rewires TNFÉ' signaling dynamics to skew susceptibility to recurrence. ELife, 2019, 8, .	6.0	24
24	Estrogen and Recurrent UTI: What Are the Facts?. Science Translational Medicine, 2013, 5, 190fs23.	12.4	15
25	Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections. , 0, , 589-646.		6